NOV 25, 2019 10:01 AM PST

Darobactin: Promising New Drug to Combat Antibiotic Resistance

WRITTEN BY: Annie Lennon

Every year, around 700,000 people are estimated to die from drug-resistant infections thanks to our overuse of antibiotics both in agriculture and medicine. With this figure estimated to grow into the millions within the coming decades, researchers are scrambling to find new ways to treat infections. Now, researchers from Justus Liebig University Giessen have discovered a new peptide from the gut of a parasitic worm that may be able to help. 

Known as Darobactin, the peptide works against gram negative bacteria which, due to their highly restrictive cell walls, are immune to most antibiotics. Gram negative bacteria are common; examples including Escherichia coli (E. Coli) and Klebsiella pneumoniae (pneumonia) which have become immune to most treatment due to this cellular feature, thus prompting heavy research into tackling gram negative bacteria. 

The epitome of two years of research, Darobactin emerged as a possible antibiotic from analyzing the Photorhabdus bacteria, found in the gut of a small parasitic worm known as a nematode. The worm first caught researchers attention due to its ability to feed on insects, targeting their larvae and releasing bacteria that combat pathogens similar to those present in the human gut. Isolating the worm’s gut bacteria, the researchers were then able to find Darobactin which, after screening, was then experimented with to treat bacterial infections common in humans. 

So far, usage of the peptide has been successful. In experiments with mice, it has successfully managed to eradicate several bacterial strains including previously antibiotic-resistant strains of E Coli and pneumonia. From examining it in the lab, researchers saw that it works by binding to the BamA protein, found on the external membrane of gram negative bacteria. This then leads the bacteria to malfunction, and eventually die off. 

According to Professor Till Schaeberie from the Institute of Insect Biotechnology, “"It is particularly interesting to note that this previously unknown weak point is located on the outside of the bacteria where substances can easily reach it." 

Although Darobactin shows a lot of promise as an upcoming antibiotic, as human trials have yet to be conducted, it will take some time for the peptide to be able to treat human infections. Despite this however, the researchers remain optimistic that their experiments with Darobactin demonstrate a clear potential for its development as a therapeutic


Sources: Science Alert, Science Daily and Nature

About the Author
  • Annie graduated from University College London and began traveling the world. She is currently a writer with keen interests in genetics, psychology and neuroscience; her current focus on the interplay between these fields to understand how to create meaningful interactions and environments.
You May Also Like
JAN 21, 2020
Drug Discovery & Development
JAN 21, 2020
New Ultrasound Treatment for Parkinson's Tremors
A non-invasive ultrasound procedure may provide lasting relief from tremors in people with Parkinson’s disease (PD) and essential tremor (ET), accord...
JAN 21, 2020
Cannabis Sciences
JAN 21, 2020
Is Cannabis Helping America Sleep?
Researchers find cannabis is being used as a sleep-aid in Colorado. Many Americans struggle with sleep disturbances -- some estimates put the percentage at...
JAN 21, 2020
Health & Medicine
JAN 21, 2020
Once-a-Month Contraceptive Pill Closer to Reality
While a variety of contraceptive options exist, each has its pros and cons. As many women understand, one of the major drawbacks of the daily birth control...
JAN 21, 2020
Drug Discovery & Development
JAN 21, 2020
Drug To Treat Ulcerative Colitis
Biomedical researchers at the University of California—Riverside, found that the therapeutic drug ‘tofacitinib’ used in treating autoimmu...
JAN 21, 2020
Drug Discovery & Development
JAN 21, 2020
New Drug to Make Breast Cancer Treatment More Affordable
The US Food and Drug Administration has granted accelerated approval to new breast cancer drug, trastuzumab deruxtecan. The drug’s increasing recogni...
JAN 21, 2020
Drug Discovery & Development
JAN 21, 2020
New Drug to Treat Migraines Approved by FDA
Over 1 in 10 people around the world- or 780 million people. Three times more common in women than in men, until now, most treatments have been preventativ...
Loading Comments...